Epithelial-mesenchymal transition is the main driver of intrinsic metabolism in cancer cell lines

Sarah Cherkaoui(University Children's Hospital Zurich), Nicola Zamboni(Scuola Internazionale Superiore di Studi Avanzati), Mauro Miguel Masiero(ETH Zurich), Alaa Othman(University of Zurich), Berend Snijder(ETH Zurich), Rebekka Wegmann(ETH Zurich), Sébastien Dubuis(ETH Zurich), Susan E. Critchlow(AstraZeneca (United Kingdom)), Jenna Bradley(AstraZeneca (United Kingdom)), Claus Bendtsen(Quantitative BioSciences), Stephan Durot(ETH Zurich)
bioRxiv (Cold Spring Harbor Laboratory)
November 4, 2021
10.1101/2021.11.02.466992
Cited by 2

Related Papers

Mapping human microbiome drug metabolism by gut bacteria and their genes
|Nature|2019|1.1k
A roadmap for interpreting 13C metabolite labeling patterns from cells
|Current Opinion in Biotechnology|2015|652
Separating host and microbiome contributions to drug pharmacokinetics and toxicity
|Science|2019|427
Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt’s lymphoma anti-tumor activity
|Oncotarget|2017|155
The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support
|Cancer Cell|2021|140